Developing therapies to treat hepatitis C infection in post-liver transplant recipients

Area of Science:

• Hepatology
• Transplant Surgery
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection is a leading cause for liver transplantation in the US.
• HCV recurrence post-transplant is nearly universal, posing significant challenges.
• Prior interferon (IFN)-based therapies had limited efficacy and tolerability, especially in decompensated liver disease.

Purpose of the Study:

• To review current pharmacotherapies for HCV recurrence in liver transplant recipients.
• To discuss the evolution of HCV treatment from IFN-based to direct-acting antivirals (DAAs).
• To provide insights into updated treatment guidelines and optimal timing for HCV therapy.

Main Methods:

• Literature review of pharmacotherapies for HCV recurrence post-liver transplant.
• Analysis of efficacy and tolerability data for various treatment regimens.
• Examination of updated clinical guidelines from major societal organizations.

Main Results:

• Direct-acting antiviral (DAA) therapies represent a paradigm shift, offering effective, all-oral, IFN-free treatment options.
• Daclatasvir/sofosbuvir and ledipasvir/sofosbuvir have demonstrated extensive study and efficacy in post-transplant settings.
• Newer pangenotypic DAAs show promise but require further evidence for routine use in liver transplant recipients.

Conclusions:

• DAAs have revolutionized HCV management, providing viable treatment for recurrence post-liver transplant.
• Established DAA regimens like daclatasvir/sofosbuvir and ledipasvir/sofosbuvir are recommended.
• Careful consideration of treatment timing (pre- vs. post-transplant) remains critical.